Skip to content
Subscriber Only

FDA Targets U.S. Marijuana Leader in CBD Marketing Crackdown

  • Curaleaf shares dip as health agency releases warning letter
  • FDA says Curealeaf CBD products are ‘unapproved new drugs’
Video player cover image
Why Curaleaf Made the $875M Deal for Grassroots Cannabis
Updated on

The most valuable marijuana company in the U.S. is under fire for how it’s marketing and selling CBD, the trendy cannabis extract now sold at national retailers.

The Food and Drug Administration sent Curaleaf Holdings Inc. President Joseph Lusardi a letter dated Monday warning the company its lotion, pain-relief patch, tincture and disposable vape pen are considered drugs because they claim to treat conditions like pain, anxiety and ADHD, according to language on its website and social media pages.